Christopher MacGriff

Dr. MacGriff serves as Inflammatix’s strategy lead, with a focus on early pipeline ideation and business development partnerships. Previously he was an investor at Northpond Ventures, where his portfolio of businesses included Inflammatix, Intabio (acquired by SCIEX), IsoPlexis (acquired by Berkely Lights), Isolation Bio, and Deep Lens (acquired by Paradigm). Prior to Northpond, he worked in strategy consulting at Health Advances, where he advised clients in the healthcare and life sciences industries. He received a PhD in electrical engineering from Arizona State University and a BS in physics from Georgetown University.